FDA: Zantac carcinogens no more dangerous than 'grilled or smoked meats'

Zantac
The FDA said levels of a possible carcinogen in tested lots of branded and generic Zantac were no higher than that found in smoked or grilled meats. (Sanofi)

Drugmakers may be recalling the heartburn med Zantac around the world, but the FDA wants consumers to stop worrying. Higher-than-recommended levels of a possible carcinogen in the pills are no more dangerous than a grilled ribeye, the agency said Monday. 

Testing of recalled lots of branded and generic Zantac showed levels of a contaminant known as N-Nitrosodimethylamine (NDMA) that were as much as nine times greater than the FDA's recommended limit––but the agency pooh-poohed the health risk in a release

Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said despite NDMA levels that were at times significantly above the acceptable limits, the amount of the compound found in the drugs was comparable to levels found in "grilled or smoked meats." Moreover, the FDA concluded that consuming Zantac didn't cause NDMA to form in the stomachs of patients, as had been previously posited.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

"We understand the concern we’ve been hearing from parents and pediatricians and we’ll continue to investigate," Woodcock said.

RELATED: FDA now says impurity level in Zantac and other antacids is too high 

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.